Small intestinal mucosal injury and its risk factors in patients with gastrointestinal cancer who developed complicated fluoropyrimidine-induced diarrhea

Table 3 Univariate and multivariate analyses of factors associated with complicated chemotherapy-induced diarrhea

Factor	Univariate analysis			Multivariate analysis
Factor	OR	95% CI	p	OR	95% CI	p
Cancer sites, stomach (/colorectum)	2.53	1.17–5.47	0.01	1.38	0.55–3.47	0.48
Sex, female (/male)	1.39	0.67–2.88	0.37
Age, ≥ 70 (/< 70)	1.26	0.58–2.72	0.54
PS, 0–1 (/ ≥ 2)	1.03	0.38–2.76	0.94
Resection of primary sites, no (/yes)	2.42	0.72–8.11	0.15
Number of metastatic sites, 0–1 (≥ 2)	1.75	0.85–3.59	0.12
Fluoropyrimidine type*, oral (/infusional)	3.59	1.52–8.47	0.003	2.95	1.06–8.19	0.03
Combination chemotherapy, yes (/no)	0.78	0.29–2.11	0.63
Platinum, yes (/no)	0.92	0.41–2.05	0.84
Irinotecan, yes (/no)	2.52	0.82–7.71	0.10
Taxane, yes (/no)	0.32	0.04–2.46	0.27
Trastuzumab, yes (/no)	0.95	0.21–4.15	0.94
Cetuximab/panitumumab, yes (/no)	0.43	0.05–3.26	0.41
Bevacizumab, yes (/no)	0.65	0.24–1.74	0.39

OR odds ratio, CI confidence interval, PS performance status
^*Oral fluoropyrimidine includes S-1 or capecitabine, and intravenous fluoropyrimidine includes 5-fluorouracil

ISSN: 1471-230X